Evacetrapib

Drug Profile

Evacetrapib

Alternative Names: LY-2484595

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antihyperlipidaemics; Benzazepines; Carboxylic acids; Cyclohexanes; Small molecules; Tetrazoles
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypercholesterolaemia; Hyperlipidaemia
  • Phase I Cardiovascular disorders
  • No development reported Atherosclerosis

Most Recent Events

  • 01 Sep 2016 Eli Lilly terminates the phase III ACCENTUATE trial in Hyperlipidaemia (Adjunctive treatment) in USA and Puerto Rico (PO) due to insufficient efficacy (NCT02227784)
  • 01 Dec 2015 Eli Lilly and Company completes a phase I trial in Dyslipidaemias in USA (NCT02168803)
  • 12 Oct 2015 Discontinued - Phase-III for Cardiovascular disorders (Prevention) in Switzerland, Sweden, Russia, Romania, Netherlands, Israel, Germany, Germany, United Kingdom, Ukraine, Turkey, South Africa, Taiwan, Belgium, China, Spain, Slovakia, Poland, Peru, Lithuania, South Korea, Japan, Italy, India, Hungary, Hungary, Hong Kong, France, Czech Republic, Bulgaria, Brazil, Austria, Puerto Rico, New Zealand, Mexico, Mexico, Estonia, Denmark, Canada, USA, Australia, Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top